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Psychotic disorders are a complex and signiﬁcant public
health problem, with heavy personal, social and health-
related costs.1 In addition to high rates of functional
impairment, disability and reduced quality of life, patients
with psychosis often have comorbid substance misuse and
frequent side-effects from their medication.1 Despite
extensive investment and highly developed community
and in-patient services, patients with psychosis also suffer
disproportionate levels of social isolation and socio-
economic deprivation.1 Studies of out-patient populations
with schizophrenia indicate that these individuals are
signiﬁcantly more likely to be unemployed, have no
formal qualiﬁcations and live in group homes.2 There have
been reports that socioeconomic status (SES) can inﬂuence
prescribing for schizophrenia. In a survey of 1342 physicians
in Germany, Franz and colleagues3 found that non-adherent
patients with schizophrenia with low SES were four times
more likely to receive conventional depot or long-acting
injections of antipsychotics than non-adherent patients of
high SES. Conversely, high-SES non-adherent patients were
more likely to be prescribed oral and long-acting depot
second-generation antipsychotics.3
Greater Glasgow and Clyde Health Board has a higher
concentration of deprived areas than the rest of Scotland,
with 43.5% of the population belonging to the most
deprived 15% of the Scottish population.4 NHS Greater
Glasgow and Clyde has developed a comprehensive case
register of patients with psychosis treated in secondary care
over the past decade, the Psychosis Clinical Information
System (PsyCIS),5 with details of over 7000 individuals
included. The PsyCIS database facilitates clinical governance
and research studies. In this report, we aimed to investigate
the impact of SES as deﬁned by the Scottish Index of
Multiple Deprivation (SIMD) category4 on prescribing for
patients with schizophrenia in Glasgow. Speciﬁcally, we
aimed to determine how SIMD category inﬂuenced rates of:
prescription of depot medication, polypharmacy (more than
two psychotropic medications), prescription of newer
second-generation antipsychotics and prescription of
clozapine.
We hypothesised that patients with schizophrenia
living in areas of high deprivation (SIMD 8-10 combined),
relative to patients living in areas of high afﬂuence (SIMD
1-3 combined), would have higher rates of prescribed
depot medications and polypharmacy and lower rates of
second-generation antipsychotic and clozapine prescribing.
Although each individual patient may beneﬁt from a
number of different medications, the prescription of
Psychiatric Bulletin (2014), 38, 54-57, doi: 10.1192/pb.bp.112.042143
1University of Glasgow; 2NHS Greater
Glasgow and Clyde; 3Royal Edinburgh
Hospital
Correspondence to Daniel J. Martin
(daniel.martin@glasgow.ac.uk)
First received 27 Nov 2012, ﬁnal
revision 9 May 2013, accepted 15 May
2013
B 2014 The Royal College of
Psychiatrists. This is an open-access
article published by the Royal College
of Psychiatrists and distributed
under the terms of the Creative
Commons Attribution License (http://
creativecommons.org/licenses/by/
3.0), which permits unrestricted use,
distribution, and reproduction in any
medium, provided the original work
is properly cited.
Aims and method To investigate whether socioeconomic status inﬂuenced rates
of depot medication prescribing, polypharmacy (more than two psychotropic
medications), newer (second-generation) antipsychotic prescribing and clozapine
therapy. Postcodes, Scottish Index of Multiple Deprivation (SIMD) categories and
current medication status were ascertained. Patients in the most deprived SIMD
groups (8-10 combined) were compared with those in the most afﬂuent SIMD groups
(1-3 combined).
Results Overall, 3200 patients with ICD-10 schizophrenia were identiﬁed. No clear
relationship between socioeconomic status and any of the four prescribing areas was
identiﬁed, although rates of depot medication use in deprived areas were slightly
higher.
Clinical implications Contrary to our hypothesis, there was no evidence that
patients with schizophrenia within NHS Greater Glasgow and Clyde who live in more
deprived communities had different prescribing experiences from patients living in
more afﬂuent areas.
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second-generation antipsychotic medication and clozapine
was felt to be a marker of good care. The reasons for
this include less extrapyramidal side-effects and that
less monitoring is required with second-generation anti-
psychotics. Higher prescription rates of clozapine were
thought to represent a pragmatic and systematic approach
to severe and enduring mental illness within a patient group
given that clozapine remains the only medication currently
licensed for the management of treatment-resistant
schizophrenia.
Method
The PsyCIS register consists of details of adult (aged 18-65
years) patients in the NHS Greater Glasgow and Clyde
Health Board area in contact with community-based mental
health services, with an ICD-10 diagnosis of F20-29, F30-
31, F32.3, F33.3 F06.0-06.2, F06.30-06.31 and F1(x) with
psychotic symptoms, diagnosed by a consultant psychiatrist
using ICD-10 criteria.5 A retrospective medical case-note
audit across Greater Glasgow and Clyde (population
approximately 1 million people) was initially undertaken
to record relevant clinical and sociodemographic data on
patients with a diagnosis code from those noted. Data were
collected over a 42-month period, from February 2002 to
August 2005. Over 8000 case notes were audited in total.
Since September 2005 any patients in contact with
community services with any of the noted diagnoses have
continued to be registered on the system using the same
methodology.
Where there was uncertainty over the primary
diagnostic coding, case notes were reviewed by the research
team in consultation with the local consultant psychiatrist
and a clinical consensus diagnostic coding was applied.
Annual update information is provided by psychiatrists
involved in the direct care of the patient and includes
updates on clinical status, treatment and sociodemographic
circumstances. The process of annual review also enabled
checking of the accuracy of information such as postcode
and current medication. Local clinicians have a two-way
relationship with the PsyCIS team, which facilitates the
return to consultants of clinically relevant information at an
individual case-load level. This study of prescribing practice
was approved by the West of Scotland NHS Research Ethics
Committee.
Overall, 3200 patients with ICD-10-diagnosed
schizophrenia were identiﬁed as having been on the
PsyCIS database between February 2002 and August 2005.
Each of these patients was allocated to a SIMD category
based on their postcode (1 =most afﬂuent, 10 =most
deprived). The index combines information from seven
domains which carry different weightings, as follows:
current income (28%), employment (28%), health (14%),
education (14%), geographic access to services (9%), crime
(5%), housing (2%).6
The most recently recorded medication information
on the PsyCIS system was extracted for each patient
along with information on gender and length of contact
with psychiatric services; this was then analysed further.
A descriptive analysis was carried out comparing
prescribing rates of depot medication, polypharmacy,
atypical antipsychotics and clozapine with SIMD category.
Chi-squared tests comparing the most afﬂuent group (SIMD
1-3 inclusive) with the most deprived group (SIMD 8-10
inclusive) were then carried out for each of the four
prescribing areas.
Results
Of the 3200 patients with ICD-10-diagnosed schizophrenia
identiﬁed, 69.1% were male. The mean number of years in
contact with services for men was 18.9 (s.d. = 12.1), and for
women 21.6 (s.d. = 13.8) (P =50.0001, 95% CI 73.580 to
71.6795); conﬁdence intervals reﬂect differences in the
mean ages between men and women. Almost half the
patients (46%, n = 1656) were within the most deprived
group, compared with only 9% (n = 335) from the most
afﬂuent group.
There were no signiﬁcant differences for gender and
age distribution between the afﬂuent and deprived groups.
In the afﬂuent group 31.9% were female (mean age 50.2
years) and in the deprived group 29.5% were female (mean
age 48.1 years). The mean age of men in the afﬂuent group
was 50.2 v. 48.1 years in the deprived group.
Depot medication prescribing
The overall rate of depot long-acting antipsychotic
prescription across both groups was 29.3% (range 22-34).
Although not statistically signiﬁcant (31% v. 26%; odds ratio
(OR) = 1.3, 95% CI 0.98-1.67, P=0.07), there was a trend
towards greater use of depot medications in patients of lower
SES.
Polypharmacy
The overall rate of polypharmacy, deﬁned as the
prescription of more than two psychotropic medications,
across both groups was 16% (range 11-18). Very similar rates
of polypharmacy were seen in the afﬂuent and deprived
groups (17% in the deprived group v. 16% in the afﬂuent
group; OR=0.92, 95% CI 0.67-1.26, P = 0.59). Furthermore,
11.81% of the total number of patients in the PsyCIS register
were prescribed more than one antipsychotic medication.
Second-generation antipsychotics
A comparison of afﬂuent and deprived groups found similar
rates of second-generation antipsychotic prescription (49%
in the deprived group v. 47% in the afﬂuent group; OR = 1.06,
95% CI 0.84-1.34, P = 0.63).
Clozapine prescription
A comparison of afﬂuent and deprived groups showed very
similar rates of clozapine prescribing, with 17% of the
deprived group being prescribed the drug compared with
19% in the afﬂuent group (OR=0.87, 95% CI 0.64-1.19,
P =0.39). Although similar rates of clozapine prescribing
were found between the different socioeconomic groups,
SIMD category 1 had a low rate of clozapine prescription
(11% of the group).
ORIGINAL PAPERS
Martin et al Socioeconomic status and prescribing for schizophrenia
55
Discussion
A rather striking ﬁnding from this study is the very high
rates of social and economic deprivation seen within this
cohort. However, overall we found no clear relationship
between SIMD category and any of the four prescribing
areas (Fig. 1). One possible explanation for this apparently
consistent prescribing approach across Glasgow might be
the strong local continuing professional development and
peer review mechanisms in place. Another possible
explanation for this encouraging ﬁnding could be the use
of the PsyCIS case register itself, which provides regular
updates and feedback to local psychiatrists about the
clinical, social and demographic features of their patients
and therefore allows regular reﬂection on and subsequent
improvements in prescribing through raised awareness and
reﬂective practice.
The differences between our ﬁndings and those of
Franz and colleagues3 are interesting. Franz et al found
that low medication adherence was associated with an
increase in selections of depot medication, and high-status
non-adherent patients tended to receive atypical oral and
atypical depot antipsychotics. They also found that non-
adherent patients of low SES were mostly prescribed
conventional and atypical depot antipsychotics. Patients
who had difﬁculty with adherence and were of lower SES
received ﬁrst-generation injectable antipsychotics four
times as often as non-adherent, high-SES patients. Possible
explanations for the differences in ﬁndings are numerous,
although different methodology should be highlighted.
Franz et al’s study was based on reports from ﬁctional
vignettes as opposed to retrospective and ongoing analysis of
case notes and electronic records in our study. The clear local
prescribing protocols and guidelines within NHS Greater
Glasgow and Clyde alongside strong support from pharmacy
services may also partially explain the differences in ﬁndings.
One possible reason for the trend (albeit not
statistically signiﬁcant) towards greater use of depot
medications in patients of lower SES may be the
phenomenon of ‘social drift’, whereby severe psychotic
disorders result in a lowering of SES. Severe psychosis is
also likely to be associated with reduced medication
adherence and behavioural disturbance, both of which
may be associated with increased rates of depot medication.
Polypharmacy was deﬁned in the PsyCIS cohort as
the prescription of two or more classes of psychotropic
medication. An Australian national survey of self-reported
medication use in 1825 participants with psychotic illness
reported that 69% of people on psychotropic medication
had been using more than one psychotropic medication in
the month prior to interview.7 The study also reported that
24.9% of patients with a psychotic illness were using more
than one antipsychotic medication, compared with 11.81% of
patients in the PsyCIS group who were prescribed more
than one antipsychotic medication. This ﬁnding further
underlines the reduced rate of polypharmacy within the
PsyCIS cohort.
Previous studies have found rates of polypharmacy of
up to 90% in patients with schizophrenia,8,9 albeit one of
the studies8 was carried out in an in-patient setting, which
may have resulted in increased rates of polypharmacy. A
large American study of 13 079 visits to ofﬁce-based
psychiatrists indicated a rise in psychotropic polypharmacy
(deﬁned as the prescription of more than two psychotropic
drugs), from 16.9% to 33.2% between 1996-1997 and 2005-
2006.10 The studies have used different methodologies, were
carried out in different settings and deﬁned polypharmacy
differently. It is still possible to make a broad comparison,
with the rates of psychotropic polypharmacy in our study
being low. The prescription of more than two psychotropic
medication classes was chosen to deﬁne polypharmacy in
this study given the presence of the American study which
was robust and thorough. The relatively low rate of
polypharmacy in our sample may be associated with clear
clinical guidelines,9 increased attention in the literature,
improved multidisciplinary input (e.g. from pharmacy) and
improved reporting of polypharmacy by medical and
nursing staff. It is also worth noting that PsyCIS highlights
prescribing and other management strategies to psychiatrists
working locally.
Rates of second-generation antipsychotic prescribing
were also similar between different socioeconomic groups.
Their widespread use may be due to the reduction in the
costs and improved availability of these medications as well
as clear guidelines on the use of atypical antipsychotic drugs
for schizophrenia. There are reports of higher rates of
second-generation or atypical antipsychotic prescribing
within an Australian population. In a 2007 study of 2365
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Fig 1 Prescribing practices in schizophrenia: afﬂuent v. deprived groups.
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out-patients with schizophrenia which had similar
methodology to our study, Wheeler reported that 81% of
patients were prescribed an atypical antipsychotic.2
Evidence emerging since 2007 and subsequent increased
awareness relating to the metabolic side-effects of these
drugs may partly explain the differences in rates noted
between Glasgow and Australia.
A comparison of afﬂuent and deprived groups showed
very similar rates of clozapine prescribing, with 17% of the
deprived group being prescribed the drug compared with
19% in the afﬂuent group. A possible reason for low
prescription rates of clozapine in the SIMD 1 group alone
(11%) could be the fact that individuals who have responded
to initial treatments may have been able to retain higher
SES. Chaotic social circumstances and high rates of
comorbid substance misuse are associated with low SES,
and are also relative contraindications for clozapine, given
the regular monitoring and follow-up required for patients
on the drug. Furthermore, treatment resistance to clozapine
is likely to be associated with a worsening socioeconomic
decline seen in schizophrenia. Investment and improve-
ments in community psychiatric services throughout
Glasgow in the past 10 years may have facilitated better
patient engagement and enabled more robust monitoring of
patients on clozapine, therefore increasing rates of prescrip-
tion across the socioeconomic groups. In their 2000 study
of in-patients, Taylor and colleagues found an overall
clozapine prescription rate of 23%.11 It is encouraging that
in Glasgow clozapine prescription rates are similar,
although the PsyCIS database is based on out-patient data.
The higher rate in Taylor and colleagues’ study may be due
to in-patients having a greater likelihood of more severe or
poorly controlled illness.
Strengths and limitations
Strengths of the study include the large and comprehensive
nature of the PsyCIS database, which is representative and
prospective in design. Regular checks of data accuracy are
carried out by the senior medical practitioners involved
in case management, therefore improving the validity
of recorded diagnoses, clinical and sociodemographic
circumstances. Regular review also ensures up-to-date
information is entered into the database.
Limitations include possible inaccuracies in data
recording or reporting, although the frequent re-checking
of notes and other sources of clinical information does
reduce this possibility. Misdiagnosis is also a consideration,
although again this is probably reduced by the use of
consultant psychiatrist-based diagnoses and the checking of
diagnoses against ICD-10 criteria.
Another possible limitation of the study is the
exclusion of patients managed solely in primary care. This
is inherent to the design of the study and would be difﬁcult
to improve on without a signiﬁcant linkage of the PsyCIS
database and primary care records. Although some patients
with psychosis are able to live independently in the
community without input from secondary services, further
study is required to ascertain numbers of patients.
Furthermore, PsyCIS also excludes those under 16 and
over 65 years old not seen by general adult community
services, in addition to those whose psychotic illness is
managed exclusively in addictions psychiatry, old age
psychiatry or learning disability services. These numbers
are likely to be relatively small and the vast majority of
patients of working age who have psychotic illness are
managed by adult general psychiatric services. It should also
be noted that using SIMD categories as a proxy measure of
deprivation introduces limitations into the study, too.
Postcode sectors that are not internally homogeneous may
contain varying levels of deprivation.
Perhaps surprisingly, there are relatively few reports in
the literature on the impact of SES on prescribing in
schizophrenia. Our ﬁndings contrast with Franz and
colleagues’ recent survey which indicated that low SES
was associated with increased rates of depot prescription
and reduced rates of atypical antipsychotic use. Franz’s
work was, however, based on the responses of physicians
rather than objective measures of prescribing, as in our
study.
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